SUPPORTING INFORMATION

Design and synthesis of cyclic lipidated peptides derived from the C-terminus of Cx43

for hemichannel inhibition and cardiac endothelium targeting

Debora Iaculli^a, Jade Montgomery^{b,c}, Arthur Lamouroux^a, Anne Caufriez^{a,d}, Rafael

Gozalbes^e, Mathieu Vinken^d, Filippo Molica^{b,c}, Brenda R. Kwak^{b,c}, Steven Ballet^{a*}

^a Research Group of Organic Chemistry, Departments of Bioengineering Sciences and Chemistry, Vrije Universiteit Brussel, Brussels, Belgium; ^b Department of Pathology and Immunology, and ^c Geneva Center for Inflammation Research, Faculty of Medicine, University of Geneva, Geneva, Switzerland; ^d Department of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, Brussels, Belgium; ^e ProtoQSAR SL, Parque Tecnológico de Valencia, Paterna (Valencia), Spain *Corresponding author. Email address: steven.ballet@vub.be

Content

1.	Circular Dichroism (CD)	
	spectra2	
2.	Biological activity	2
3.	Peptide characterization	4
	3a. HPLC chromatograms of	
	peptides4	
	3b. Characterization	15

1. Circular Dichroism (CD) spectra



Figure S1. CD spectra of linear peptide **CT10** (blue) and cyclic analogue **11** (yellow) at 200 μ M concentration in mQ water. A minimum at 200 nm indicates a random coil conformation.

2. Biological activity

	ATP release ^a	SEM				
Control	38.4228	3.8230				
Calcium-free	100	/				
Cbx	43.7932	5.5259				
Triton	248.6069	26.2110				
TAT-Gap19 100 μM	215.7692	16.4991				
TAT-Gap19 50 μM	127.3083	5.5652				
TAT-Gap19 10 μM	59.2634	2.5058				
TAT-Gap19 5 μM	47.4886	1.8262				
TAT-Gap19 1 μM	47.6801	6.1592				
TAT-Gap19 0.1 μM	54.7775	8.0668				
Gap19 100 µM	82.8115	4.2932				
Gap19 5 μM	75.4661	2.7612				
Gap27 100 µM	81.9131	4.8462				
Gap27 5 μM	67.1248	12.4100				
αCT1 100 μΜ	106.6684	26.5628				
αCT1 5 μM	38.9928	2.9283				
allogn normalized to calcium free condition						

Table S1. ATP release data shown in Figure 5a.

^aMean normalized to calcium-free condition.

Table S2. ATP release data shown in **Figure 5b**. All compounds are used at 5 µM concentration unless otherwise stated.

	ATP release ^a	SEM
Control	49.3877	3.5875
Calcium-free	100	/

Cbx 25 μM	60.4766	7.7089
Gap19	53.6525	6.9376
Gap27	58.4393	5.0960
TAT-Gap19	39.8281	3.6046
αCT1	41.1484	2.3267
CT10	55.4854	3.5503
1	56.0797	4.7121
2	53.0107	4.3760
3	58.4702	4.6215
4	66.2402	8.3886
5	55.5167	5.0309
6	53.7892	5.7785
7	54.2125	4.6657
8	47.8943	6.1749
9	46.7801	5.8877
10	54.7488	7.8867
11	43.9668	4.0310
12	46.6075	5.0229
13	43.8298	4.8075
14	46.2794	4.9171
Palm-CT10	44.6669	4.0904
Palm-Gap19	54.6035	5.4062
15	133.7852	28.8214
16	67.2242	7.8381
17	72.5860	15.9468

^aMean normalized to calcium-free condition.

Table S3. ATP release	data	shown	in	Figure	6b.

	ATP release ^a	SEM
Control	54 5982	4 6247
Calcium-free	100	/
Chx 25 µM	78 1965	8 6963
Gan27 5 µM	57 8875	5 2452
Gap27 0 1 µM	55 6856	1 3/60
	27 8100	1.5400
$TAT Cop 10.0.1 \dots M$	44 7607	4.0903
	44.7097	2 1507
		5.1507
	50.5858	5.4295
115 μΜ	43.9424	5.5982
11 0.1 μΜ	52.4234	4.9713
12 5 μΜ	62.4101	6.1084
12 0.1 μΜ	57.9562	9.9702
13 5 μΜ	51.4148	7.3095
13 0.1 μΜ	79.7386	20.1216
14 5 μΜ	54.5492	7.2228
14 0.1 μΜ	70.4794	12.3845
Palm-CT10 5 µM	58.4669	12.1414
Palm-CT10 0.1 μM	50.8713	4.5227
Palm-Gap19 5 µM	49.4210	6.9054
Palm-Gap19 0.1 µM	55.9035	7.7251
15 5 μΜ	133.7852	28.8214
15 0.1 μΜ	81.9773	5.9136
16 5 μΜ	77.0091	12.0120
16 0.1 μΜ	44.8448	3.5623

17 5 μΜ	72.5860	15.9468
17 0.1 μΜ	54.4498	7.2777
18 5 μM	61.6970	5.0018
18 0.1 μM	52.2265	7.4227

^aMean normalized to calcium-free condition.

Table S4. ATP release data shown in **Figure 8b**. All compounds are used at 5 µM concentration unless otherwise stated.

	Parental H	eLa	HeLa-Cx43			
	ATP release ^a	SEM	EM ATP release ^a			
Control	1.7647	0.1682	4.0067	0.2481		
Calcium-free	1.7919	0.4219	18.2058	1.2244		
Cbx 25 μM	0.9207	0.0167	2.1867	0.5339		
Gap27	0.9529	0.0983 9.3690		0.9358		
TAT-Gap19	1.3701	0.2847 10.9629		0.7689		
αCT1	1.6218	0.4958 9.6282		0.1351		
11	1.5371	0.4916 8.7419		0.9250		

^aMean (in nM).

Table S5. ATP release data shown in *Figure 8c*. All compounds are used at 5 μM concentration unless otherwise stated.

	Parental SK-	HEP-1	SK-HEP-1-Cx43			
	ATP release ^a SEM		ATP release ^a	SEM		
Control	10.0176	1.5382	30.0127	3.2453		
Calcium-free	28.7505	4.9305	92.3906	17.9121		
Cbx 25 μM	13.9931	2.4139	26.4826	3.7740		
Gap27	8.5784	0.9461	36.9304	1.2387		
TAT-Gap19	15.3639	2.1802	55.5511	7.7043		
αCT1 6.6804		1.0241 39.5655		4.5254		
11	7.9522 0.394		38.4712	1.9023		

^aMean (in nM).

3. Peptide characterization

3a. HPLC chromatograms of peptides

































3b. Characterization

Table S6. a)[M+H]+; (b) as determined by RP-HPLC; (c) [M+2H]++. Azp = (4S)-4-azidoproline, Pra = propargylglycine, Azk = azidolysine, Palm = palmitic acid, Ahx = 6-aminohexanoic acid. Residues between squares? are part of the peptide macrocycle.

Dentide	Sequence	MW	HRMS	HRMS	Rt ^(b)	Yield	Purity	Formatula
Peptide		(TFA salt)	calculated ^(a)	found ^(a)	(min)	(%)	(%)	Formula
	H-Arg-Gln-Pro-Lys-Ile-Trp-Phe-Pro-Asn-Arg-Arg-Lys-Pro-Trp-Lys-Lys-	4200.00	1629.4277 ^(c)	1629.4271 ^(c)	1.78	17	95	C150U220N40024
acti	Arg-Pro-Arg-Pro-Asp-Asp-Leu-Glu-Ile-OH	4398.09						C150H256N46054
CT10	H-Ser-Arg-Pro-Arg-Pro-Asp-Asp-Leu-Glu-Ile-OH	1539.37	1197.6228	1197.6255	1.58	55	>99	C50H84N16O18
Gap19	H-Lys-Gln-Glu-Ile-Lys-Lys-Phe-Lys-OH	1731.57	1161.7360	1161.7383	1.52	49	99	C55H96N14O13
TAT-Gap19	H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Gln-Ile-Glu-Ile- Lys-Lys-Phe-Lys-OH	4185.60	1351.8419 ^(c)	1351.8451 ^(c)	1.56	34	>99	C119H212N46O26
Gap27	H-Ser-Arg-Pro-Thr-Glu-Lys-Thr-Ile-Phe-Ile-Ile-OH	1646.63	1304.7578	1304.7594	2.03	49	>99	C49H85N13O12
1 (SBL-CX43-106)	Ac-Ser-Arg-Pro-Arg-Pro-Asp-Asp-Leu-Glu-Ile-OH	1467.38	1239.6333	1239.6327	1.62	77	>99	C52H86N16O19
2 (SBL-CX43-107)	H-Ser-Arg-Pro-Arg-Pro-Asp-Asp-Leu-Glu-Ile-NH ₂	1538.37	1196.6388	1196.6404	1.47	16	99	C50H85N17O17
3 (SBL-CX43-108)	H-Ser-Ala-Pro-Arg-Pro-Asp-Asp-Leu-Glu-Ile-OH	1340.25	1112.5588	1112.5626	1.59	22	99	C47H77N13O18
4 (SBL-CX43-109)	H-Ser-Arg-Pro-Ala-Pro-Asp-Asp-Leu-Glu-Ile-OH	1340.25	1112.5588	1112.5614	1.61	44	98	C47H77N13O18
5 (SBL-CX43-110)	H-Ser-Arg-Pro-Arg-Pro-Ala-Asp-Leu-Glu-Ile-OH	1495.38	1153.6329	1153.6359	1.54	23	>99	C49H84N16O16
6 (SBL-CX43-111)	H-Ser-Arg-Pro-Arg-Pro-Asp-Ala-Leu-Glu-Ile-OH	1495.38	1153.6329	1153.6375	1.60	42	>99	C49H84N16O16
7 (SBL-CX43-112)	H-Ser-Arg-Pro-Arg-Pro-Asp-Asp-Leu-Ala-Ile-OH	1481.35	1139.6173	1139.6201	1.53	13	99	C48H82N16O16
8 (SBL-CX43-113)	H-Ser-Arg-Ala-Arg-Pro-Asp-Asp-Leu-Glu-Ile-OH	1513.35	1171.6072	1171.6097	1.50	20	99	C48H82N16O18
9 (SBL-CX43-114)	H-Ser-Arg-Pro-Arg-Ala-Asp-Asp-Leu-Glu-Ile-OH	1513.35	1171.6072	1171.6073	1.54	48	>99	C48H82N16O18
10 (SBL-CX43-147)	H-Ser-Arg-Ala-Arg-Ala-Asp-Asp-Leu-Glu-Ile-OH	1487.31	1145.5914	1145.5938	1.48	19	>99	C46H80N16O18
11 (SBL-CX43-125)	Ac-Ser-Arg-Pro-Arg- [Azp -Asp-Asp-Leu-Glu- Pra] -NH ₂	1489.37	1261.6038	1261.6045	1.30	14	99	C51H80N20O18
12 (SBL-CX43-138)	Ac-Ser-Arg-Pro-Arg- c[Pra -Asp-Asp-Leu-Glu- Azk] -NH ₂	1505.41	1277.6351	1277.6340	1.33	9	>99	C52H84N20O18
13 (SBL-CX43-139)	Ac-Ser-Arg-Pro-Arg- c[Azp -Asp-Asp- Pra] -Glu-Ile-NH ₂	1489.37	1261.6038	1261.6038	1.30	9	>99	C51H80N20O18
14 (SBL-CX43-140)	Ac- c[Pra -Arg-Pro-Arg- Azk] -Asp-Asp-Leu-Glu-Ile-NH ₂	1531.49	1303.6871	1303.6846	1.50	4	95	C55H90N20O17
Palm-CT10 (SBL-CX43-135)	Palm-Ser-Arg-Pro-Arg-Pro-Asp-Asp-Leu-Glu-Ile-OH	1663.78	1435.8524	1435.8545	2.71	26	99	C66H114N16O19
Palm-Gap19 (SBL-CX43-137)	Palm-Lys-Gln-Ile-Glu-Ile-Lys-Lys-Phe-Lys-OH	1855.97	1399.9656	1399.9698	2.89	31	>99	C71H126N14O14
15 (SBL-CX43-152)	Palm-ELys-PEG-Ser-Arg-Pro-Arg-Pro-Asp-Asp-Leu-Glu-Ile-OH	2051.13	1709.0212	1709.0217	2.57	6	98	C78H137N19O23
16 (SBL-CX43-153)	Palm-ELys-Ser-Arg-Pro-Arg-Pro-Asp-Asp-Leu-Glu-Ile-OH	1905.98	1563.9474	1563.9469	3.01	11	98	C72H126N18O20
17 (SBL-CX43-154)	Palm-Lys-Ser-Arg-Pro-Arg-Pro-Asp-Asp-Leu-Glu-Ile-OH	1905.98	1563.9474	1563.9492	2.89	24	98	C72H126N18O20
18 (SBL-CX43-157)	Palm-ɛLys-Ser-Arg-Pro-Arg- c[Azp -Asp-Asp-Leu-Glu- Pra] -NH ₂	1927.95	1585.9178	1585.9183	2.89	4	98	C71H120N22O19
19 (SBL-CX43-158)	Palm-ɛLys-Ser-Arg-Pro-Arg- c[Azp -Asp-Asp-Leu-Glu- Pra] -Ahx- Lys(Fluorescein)-Ahx-Cys-Arg-Pro-Pro-Arg-NH ₂	3476.57	1454.2767 ^c	1454.2802 ^c	2.88	2	95	C135H207N37O33S
20 (SBL-CX43-159)	Palm-ɛLys-Ser-Arg-Pro-Arg- c[Azp -Asp-Asp-Leu-Glu- Pra] -Ahx- Lys(Fluorescein)-NH ₂	2525.61	1093.0762 ^c	1093.0773 <i>°</i>	2.98	2	96	C104H153N25O27
21 (SBL-CX43-160)	Ac-Ser-Arg-Pro-Arg- c[Azp -Asp-Asp-Leu-Glu- Pra] -Ahx- Lys(Fluorescein)-Ahx-Cys-Arg-Pro-Pro-Arg-NH ₂	3037.99	1292.1196 <i>°</i>	1292.1194 ^c	1.99	1	95	C115H167N35O32S